BIOLASE Beheer

Beheer criteriumcontroles 4/4

De CEO BIOLASE is John Beaver, benoemd in Feb2021, heeft een ambtstermijn van 3.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 420.69K, bestaande uit 89.1% salaris en 10.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde $ 0.60. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 3.3 jaar.

Belangrijke informatie

John Beaver

Algemeen directeur

US$420.7k

Totale compensatie

Percentage CEO-salaris	89.1%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.0003%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

Analyse CEO-vergoeding

Hoe is John Beaver's beloning veranderd ten opzichte van BIOLASE's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$16m
Jun 30 2024	n/a	n/a	-US$27m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$421k	US$375k	-US$38m
Sep 30 2023	n/a	n/a	-US$42m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$733k	US$375k	-US$29m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	US$5m	US$396k	-US$17m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$36m
Dec 31 2020	US$370k	US$308k	-US$34m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$447k	US$325k	-US$18m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$20m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$629k	US$325k	-US$22m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$566k	US$75k	-US$21m

Compensatie versus markt: De totale vergoeding ($USD 420.69K ) John } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Beaver (63 yo)

3.8yrs

Tenure

US$420,692

Compensatie

Mr. John R. Beaver has been the Chief Executive Officer and President of BIOLASE, Inc. since February 23, 2021 and has been its Director since March 2021. Mr. Beaver served as the Chief Financial Officer s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Beaver	President	3.8yrs	US$420.69k	0.00033% $ 0.6
Jennifer Bright	Chief Financial Officer	3.6yrs	US$361.13k	0.00043% $ 0.8
Steven Sandor	Chief Operating Officer	2.3yrs	US$341.54k	0.00054% $ 1.0
Michael Carroll	Corporate Secretary	no data	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIOL.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Beaver	President	3.7yrs	US$420.69k	0.00033% $ 0.6
Jonathan Lord	Independent Chairman of the Board	10.3yrs	US$112.50k	0.0025% $ 4.6
Kathleen O'Loughlin	Independent Director	3.3yrs	US$78.38k	0% $ 0
Martha Somerman	Independent Director	3.3yrs	US$80.87k	0% $ 0
Kenneth Yale	Independent Director	2.6yrs	US$78.38k	0.0011% $ 2.0

3.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOL.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

BIOLASE Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

BIOLASE, Inc., Annual General Meeting, May 02, 2024

Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc

BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022

BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer

High number of new directors

BIOLASE, Inc. Announces Election of Board of Directors

Recent updates

Motion for Joint Administration Approved for BIOLASE, Inc.

BIOLASE, Inc. Filed for Bankruptcy

The Nasdaq Stock Market to Delist Common Stock of BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024

BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

BIOLASE, Inc. to Report Q4, 2023 Results on Mar 21, 2024

BIOLASE, Inc., Annual General Meeting, May 02, 2024

BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $7.031795 million.

Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc

BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial

BIOLASE, Inc. has filed a Follow-on Equity Offering.

BIOLASE Receives Non-Compliance Notice From Nasdaq

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol

BIOLASE, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $4.5 million.

BIOLASE Provides Non-Compliance Update

BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023

BIOLASE, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Listing Qualifications Staff of Nasdaq Determines to Delist BIOLASE's Common Stock from the Nasdaq Capital Market and to Suspend Trading of the Common Stock at the Opening of Business on June 20 2023

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. to Report Q1, 2023 Results on May 11, 2023

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

BIOLASE Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

PIPStek LLC Files Patent Infringement Lawsuit Against BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

BIOLASE, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022

Biolase partners with dental speciality programs across U.S.

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

BIOLASE, Inc. Announces Election of Board of Directors

BIOLASE, Inc. to Report Q1, 2022 Results on May 12, 2022

BIOLASE: Bad News Across The Board - Sell

Price target decreased to US$2.13

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nasdaq Grants BIOLASE 180-Day Extension to Meet Minimum Bid Price Requirement

Third quarter 2021 earnings released: US$0.022 loss per share (vs US$0.21 loss in 3Q 2020)

High number of new directors

Price target increased to US$2.25

Independent Director Garrett Sato has left the company

Independent Director Michael DiTolla has left the company

Second quarter 2021 earnings released: US$0.005 loss per share (vs US$0.12 loss in 2Q 2020)